Major Scope
- Cardiovascular Case Reports
- Oncology Case Reports
- Surgical Case Reports
- Gastroenterological Case Reports
- Neurological Case Reports
- Dermatological Case Reports
- Respiratory Case Reports
- Obstetrics/Gynecology Case Reports
- Nephrology Case Reports
- Immunology Case Reports
- Paediatric Case Reports
- Orthopedics Case Reports
- Dental Case Reports
Abstract
Citation: Ann Clin Case Rep. 2023;8(1):2522.DOI: 10.25107/2474-1655.2522
Guillain-Barré Syndrome Related to Pembrolizumab in Metastatic Triple Negative Breast Cancer
Wu D, Liu Y, Zhao J* and Zheng L*
Department of Neurology, Minhang Hospital, Fudan University, China
PDF Full Text Case Report | Open Access
Abstract:
Immune Checkpoint Inhibitors (ICIs) are increasingly application in the treatment of advanced cancers these years, exhibiting the potential to be the primary method in oncotherapy. However, with the applying of ICIs, the immune-related Adverse Events (irAEs) were also reported gradually. Here, we reported a 51-year-old female with metastatic Triple Negative Breast Cancer (TNBC) developing into Guillain-Barré Syndrome (GBS) after receiving four months of anti-Programmed cell Death protein 1 (PD-1) antibodies treatment with pembrolizumab and we discussed the diagnose and treatment of GBS related to irAEs.
Keywords:
ICI; TNBC; GBS; PD-1
Cite the Article:
Wu D, Liu Y, Zhao J, Zheng L. Guillain-Barré Syndrome Related to Pembrolizumab in Metastatic Triple Negative Breast Cancer. Ann Clin Case Rep. 2023; 8: 2522..
Journal Basic Info
- Impact Factor: 5.253*
- H-Index: 6
- ISSN: 2474-1655
- DOI: 10.25107/2474-1655
- PubMed NLM ID: 101702800
Search Our Journal
Journal Indexed In
